Aqueduct Medical is developing an innovative technology for use in dilating the uterine cervix and various other body cavities.
Market & Unmet Need:
Approximately 3 million cervical dilations are performed annually in the United States for the purpose of intra-uterine procedures including: abortions, hysteroscopies, and other dilation & curettages. Cervical dilation allows medical practitioners greater access to the inside of the uterus in order to insert surgical tools for the completion of intra-uterine procedures.
Until now, there have been primarily two techniques for dilating the cervix. The first technique is the insertion of laminaria (dry, sterile seaweed) into the cervix. When laminaria comes into contact with body fluids, it expands and enlarges the opening of the cervix. Often, this process requires two patient visits and approximately 10-12 hours for sufficient dilation to occur. The second technique, referred to as Hegar dilation, involves the insertion and removal of metal rods that are graduated in increasing diameter. This process is painful, requiring the use of anesthesia, and is associated with a risk of uterine and cervix damage (cervical incompetence).
Technology & Product:
Company's first product offers an innovative dilator that combines the advantages of the Hegar dilation (i.e. – short dilation time of the whole cervix) with the advantages of laminaria (i.e. moderate redial dilation with minimal risk for false route, perforation or future cervical incompetence)
Strong IP coverage.
The Aqueduct device will be marketed in the United States as a Class II medical device, which is subject to 510(k) requirements and According to the European Medical Device Directive the device is a Class IIa device.
Develop the product until market approval, while seeking collaboration (expecting an upfront payment, milestones and royalties deal) with a global strategic player for the marketing phase. Deal value will depend mainly on phase of development and clinical results.
Present status: Design of the first prototype for Ex-Vivo human study.
Planned Milestones: After securing $700K the company will develop the first prototype to proof the concept and to commence the Ex-vivo study followed by human trials.